Welcome to our dedicated page for Bemis Company news (Ticker: BMS), a resource for investors and traders seeking the latest updates and insights on Bemis Company stock.
Bemis Co., Inc. (symbol: BMS) is a distinguished leader in the packaging industry, offering innovative solutions tailored to the food, healthcare, and pharmaceutical sectors. Founded by Judson Moss Bemis in 1858 and headquartered in Neenah, WI, the company has a rich heritage of excellence and innovation. Bemis operates through two primary segments: U.S. Packaging and Global Packaging.
U.S. Packaging Segment: This segment focuses on manufacturing operations within the United States, providing comprehensive packaging solutions for food, consumer, and industrial products. The company is known for its high-quality and durable packaging that meets the stringent standards of various industries.
Global Packaging Segment: This segment encompasses packaging-related manufacturing operations outside of the United States, including specialized packaging for medical devices and pharmaceuticals. Bemis leverages its global reach to offer innovative and reliable packaging solutions, ensuring product safety and integrity across borders.
Recently, Bemis Co., Inc. has been actively involved in several key projects and partnerships aimed at advancing packaging technology and improving sustainability. The company’s financial condition remains robust, supported by strategic investments and continuous improvements in operational efficiencies. Notable collaborations include partnerships with leading healthcare and pharmaceutical companies to develop cutting-edge packaging solutions that enhance the shelf life and integrity of medical products.
Bemis’ commitment to innovation and quality has been recognized globally, with numerous awards and accolades for its pioneering work in the packaging industry. The company continues to push the envelope by investing in research and development to create next-generation packaging materials that are both eco-friendly and cost-effective.
Stay updated with the latest developments at Bemis Co., Inc. as the company continues to lead the way in packaging innovation, quality, and sustainability.
K36 Therapeutics announced multiple poster presentations at the 66th American Society of Hematology (ASH) Annual Meeting, highlighting the first clinical data for their MMSET/NSD2 inhibitors, KTX-1001 and KTX-1029. The presentations will cover the dose escalation part of KTX-1001's Phase 1 study, showing increased exposure and decreased H3K36me2 biomarker, indicating clear target engagement. KTX-1029, a potent and selective MMSET inhibitor, demonstrated efficacy in preclinical models. Together, these data support the rationale for targeting MMSET in multiple myeloma. The favorable tolerability profile of KTX-1001 and promising clinical activity suggest its potential as a first-in-class therapy for t(4;14) multiple myeloma patients.
AVEO Oncology reported Q3 2021 revenue of $15.2 million, significantly up from $3.6 million in Q3 2020, driven largely by FOTIVDA® sales of $14.3 million. The company saw a 113% increase in quarterly revenue from the previous quarter, bolstered by the growing demand for FOTIVDA in treating relapsed/refractory renal cell carcinoma. Enrollment for the Phase 3 TiNivo-2 trial of tivozanib in combination with OPDIVO® has begun. Additionally, ficlatuzumab received Fast Track Designation from the FDA. AVEO ended the quarter with $94 million in cash and anticipates maintaining operations for at least 12 months.
FAQ
What does Bemis Co., Inc. specialize in?
When was Bemis Co., Inc. founded?
Where is Bemis Co., Inc. headquartered?
What are the main segments of Bemis Co., Inc.?
What industries does Bemis Co., Inc. serve?
What recent achievements has Bemis Co., Inc. made?
Who are some of the key partners of Bemis Co., Inc.?
What is the focus of Bemis Co., Inc.'s Global Packaging segment?
How does Bemis Co., Inc. ensure product safety and integrity?
How does Bemis Co., Inc. contribute to sustainability?
